EMEA-002004-PIP01-16
Key facts
| Active substance |
Atacicept
|
| Therapeutic area |
Immunology-Rheumatology-Transplantation
|
| Decision number |
P/0249/2017
|
| PIP number |
EMEA-002004-PIP01-16
|
| Pharmaceutical form(s) |
Solution for injection
|
| Condition(s) / indication(s) |
Treatment of Systemic Lupus Erythematosus (SLE)
|
| Route(s) of administration |
Subcutaneous use
|
| Contact for public enquiries |
Merck KGaA
Tel. +49 6151 725200 |
| Decision type |
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
|